… including strokes in patients with non-valvular AF [3–6]. The use of warfarin therapy increases
… Patients prescribed with either dabigatran or edoxaban were not included because of their …

… (DOACs) over warfarin in patients with nonvalvular AF because … 0.54/100 person-years), but
the bleeding rate in the apixaban … patients treated with apixaban, dabigatran, or rivaroxaban, …

… cohort study, for example, most patients (≈90%) using low-dose … warfarin (rivaroxaban
1.9%, dabigatran 1.8%, apixaban 1.3%, and … Asian patients with non-valvular AF have different …

… safety of dabigatran compared with warfarin in patients with … In each of the low-dose (DE220)
and high-dose (DE300) … This was also true for rivaroxaban and apixaban; patients receiving …

… rates of major bleeding (MB) in patients with atrial fibrillation. … comparing apixaban to
dabigatran, rivaroxaban, or warfarin. … both standard-dose and low-dose apixaban, with a …

… DOACs (dabigatran, rivaroxaban, apixaban, … low-dose apixaban, dabigatran, and edoxaban
were all associated with lower risks of thromboembolism and major bleeding than warfarin. …

… dabigatran 300 mg, rivaroxaban 20 mg, apixaban 10 mg, or edoxaban 60 mg per day. Any
other lower-dose regimen were defined as the low-dose … OACs, including warfarin and direct …

… (dabigatran, rivaroxaban, apixaban, or edoxaban) versus … with warfarin, all NOACs reduced
the risks of bleeding events … 50% of patients received reduced or low dose of dabigatran, …

… : “dabigatran OR apixaban OR rivaroxaban OR warfarin OR direct oral anticoagulant OR
DOAC” AND “non-valvular atrial fibrillation OR atrial fibrillation” … prescribed a “low-dose” DOAC. …

… to apixaban; similar findings were also reported for dabigatran and rivaroxaban [8], [18], [19],
[20], [21]. … database of NVAF patients newly initiating apixaban or warfarin showed a lower …